Survival during renal replacement therapy among African Americans infected with HIV Type 1 in urban Baltimore, Maryland

Clinical Infectious Diseases

Volumn 45, Issue 12, 2007, Pages 1625-1632

  Atta, Mohamed G ^a,c   Fine, Derek M ^a   Kirk, Gregory D ^a,b   Mehta, Shruti H ^b   Moore, Richard D ^a,b   Lucas, Gregory M ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; SERUM ALBUMIN;

ADULT; AFRICAN AMERICAN; AGE DISTRIBUTION; ALBUMIN BLOOD LEVEL; ARTICLE; CD4+ T LYMPHOCYTE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPLAN MEIER METHOD; KIDNEY FAILURE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RENAL REPLACEMENT THERAPY; SURVIVAL RATE; UNITED STATES; CHRONIC KIDNEY FAILURE; ETHNOLOGY; MIDDLE AGED;

ADULT; AFRICAN AMERICANS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BALTIMORE; COHORT STUDIES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL REPLACEMENT THERAPY;

EID: 39449108754     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/523728     Document Type: Article

References (31)

1. Rostand SG, Kirk KA, Rutsky EA, Pate BA. Racial differences in the incidence of treatment for end-stage renal disease. N Engl J Med 1982; 306:1276-9.
2. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Stamler J. End-stage renal disease in African-American and white men. 16-year MRFIT findings. JAMA 1997; 277:1293-8.
3. Abbott KC, Hypolite I, Welch PG, Agodoa LY. Human immunodeficiency virus/acquired immunodeficiency syndrome-associated nephropathy at end-stage renal disease in the United States: patient characteristics and survival in the pre highly active antiretroviral therapy era. J Nephrol 2001; 14:377-83.
4. Centers for Disease Control and Prevention. Epidemiology of HIV/AIDS - United States, 1981-2005. MMWR Morb Mortal Wkly Rep 2006; 55:589-92.
5. Eggers PW, Kimmel PL. Is there an epidemic of HIV Infection in the US ESRD program? J Am Soc Nephrol 2004; 15:2477-85.
6. Ifudu O, Mayers JD, Matthew JJ, et al. Uremia therapy in patients with end-stage renal disease and human immunodeficiency virus infection: has the outcome changed in the 1990s? Am J Kidney Dis 1997; 29:549-52.
7. Ortiz C, Meneses R, Jaffe D, Fernandez JA, Perez G, Bourgoignie JJ. Outcome of patients with human immunodeficiency virus on maintenance hemodialysis. Kidney Int 1988; 34:248-53.
8. Tebben JA, Rigsby MO, Selwyn PA, Brennan N, Kliger A, Finkelstein FO. Outcome of HIV infected patients on continuous ambulatory peritoneal dialysis. Kidney Int 1993; 44:191-8.
9. Kimmel PL, Umana WO, Simmens SJ, Watson J, Bosch JP. Continuous ambulatory peritoneal dialysis and survival of HIV infected patients with end-stage renal disease. Kidney Int 1993; 44:373-8.
10. Ahuja TS, Borucki M, Grady J. Highly active antiretroviral therapy improves survival of HIV-infected hemodialysis patients. Am J Kidney Dis 2000; 36:574-80.
11. Ahuja TS, Grady J, Khan S. Changing trends in the survival of dialysis patients with human immunodeficiency virus in the United States. J Am Soc Nephrol 2002; 13:1889-93.
12. Moore RD. Understanding the clinical and economic outcomes of HIV therapy: the Johns Hopkins HIV clinical practice cohort. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17(Suppl 1):S38-41.
13. Vlahov D, Anthony JC, Munoz A, et al. The ALIVE study, a longitudinal study of HIV-1 infection in intravenous drug users: description of methods and characteristics of participants. NIDA Res Monogr 1991; 109:75-100.
14. US Renal Data System. USRDS 2006 annual data report: atlast of end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2006. Available at: http://www.usrds.org.
15. Monahan M, Tanji N, Klotman PE. HIV-associated nephropathy: an urban epidemic. Semin Nephrol 2001; 21:394-402.
16. Centers for Disease Control and Prevention. Epidemiology of HIV/AIDS - United States, 1981-2005. MMWR Morb Mortal Wkly Rep 2006; 55:589-92.
17. Detels R, Munoz A, McFarlane G, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA 1998; 280:1497-503.
18. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-60.
19. Schwartz EJ, Szczech LA, Ross MJ, Klotman ME, Winston JA, Klotman PE. Highly active antiretroviral therapy and the epidemic of HIV+ end-stage renal disease. J Am Soc Nephrol 2005; 16:2412-20.
20. Macrae J, Friedman AL, Eggers P, Friedman EA. Improved survival in HIV-infected African-Americans with ESRD. Clin Nephrol 2005; 64:124-8.
21. Rodriguez RA, Sen S, Mehta K, Moody-Ayers S, Bacchetti P, O'Hare AM. Geography matters: relationships among urban residential segregation, dialysis facilities, and patient outcomes. Ann Intern Med 2007; 146:493-501.
22. Lucas GM, Griswold M, Gebo KA, Keruly J, Chaisson RE, Moore RD. Illicit drug use and HIV-1 disease progression: a longitudinal study in the era of highly active antiretroviral therapy. Am J Epidemiol 2006; 163:412-20.
23. United States Renal Data System. Mortality and causes of death. 2006. Available at: http://www.usrds.org/2006/ref/H_morte_06.pdf. Accessed 12 June 2007.
24. Acchiardo SR, Moore LW, Latour PA. Malnutrition as the main factor in morbidity and mortality of hemodialysis patients. Kidney Int Suppl 1983; 16:S199-203.
25. Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990; 15:458-82.
26. Lowrie EG, Lew NL. Commonly measured laboratory variables in hemodialysis patients: relationships among them and to death risk. Semin Nephrol 1992; 12:276-83.
27. Owen WF, Lew NL, Liu Y, Lowrie EG, Lazarus JM. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 1993; 329:1001-6.
28. Estrella M, Fine DM, Gallant JE, et al. HIV type 1 RNA level as a clinical indicator of renal pathology in HIV-infected patients. Clin Infect Dis 2006; 43:377-80.
29. Wali RK, Drachenberg CI, Papadimitriou JC, Keay S, Ramos E. HIV-1-associated nephropathy and response to highly-active antiretroviral therapy. Lancet 1998; 352:783-4.
30. Scialla JJ, Atta MG, Fine DM. Relapse of HIV-associated nephropathy after discontinuing highly active antiretroviral therapy. AIDS 2007; 21:263-4.
31. Atta MG, Gallant JE, Rahman MH, et al. Antiretroviral therapy in the treatment of HIV-associated nephropathy. Nephrol Dial Transplant 2006; 21:2809-13.